1 completed, 1 not yet recruiting, 1 withdrawn. 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow PQQ Cofactor: new trials by email Literature Review of PQQ Cofactor trials Research Report on PQQ Cofactor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PQQ for Cognitive and Negative Symptoms Pyrroloquinoline quinone (PQQ), placebo (dietary fiber) - Schizophrenia, Cognitive Symptoms | Not applicable | Not yet recruiting | Tianjin Anding Hospital | 70 | 2026-02-15 | 2026-02-10 |
| Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes Pyrroloquinoline quinone (PQQ), Placebo with soybean oil - Maternal Obesity | Early Phase 1 | Withdrawn | University of Oklahoma | 2024-12-01 | 2025-02-13 | |
| Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® ) - Glaucoma, Neuroprotection | Phase 3 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 40 | 2024-01-27 | 2025-05-01 |
Glaucoma (1) · Neurobehavioral Manifestations (1) · Ornithine Carbamoyltransferase Deficiency Disease (1) · Pregnancy in Obesity (1) · Schizophrenia (1)
Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Tianjin Anding Hospital (1) · University of Oklahoma (1)
Italy (1) · United States (1)
Ciro Costagliola, MD (1) · Marty Maxted, MD (1)